Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
update
/
details

IMAC Holdings Inc. Unveils Ignite Proteomics Subsidiary and Introduces Innovative Precision Oncology Case Study Featuring RPPA Technology

NextEdge Admin

20 Sep 2024

2 min 15 sec

Ignite Proteomics,Proteomics,Reverse Phase Protein Array

IMAC Holdings, a leader in innovative healthcare solutions, announces the launch of a groundbreaking precision oncology assay for breast cancer treatment decision-making through its new subsidiary, Ignite Proteomics LLC. This assay utilizes Reverse Phase Protein Array (RPPA) technology, following IMAC’s strategic acquisition of key assets from Theralink Technologies. The launch is highlighted by a landmark case study, published in *npj Precision Oncology*, titled "Proteomics-based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer." This study showcases the power of RPPA technology in guiding personalized oncology treatments.

Ignite Proteomics offers the first commercially available, clinically validated assay that measures both protein expression and activation levels in breast tumors, providing superior insights for targeted cancer therapies. The clinical significance of the assay was demonstrated in a 57-year-old patient with metastatic triple-negative breast cancer (TNBC), who showed disease progression despite multiple treatments. Ignite's RPPA assay identified HER2 protein activation, missed by next-generation sequencing (NGS) and other methods. This led to treatment with trastuzumab deruxtecan (T-DXd), resulting in a complete response after nine cycles.

“This innovative assay represents a major advancement in breast cancer management, offering critical insights for more precise and effective treatments,” said Faith Zaslavsky, CEO of IMAC Holdings and Ignite Proteomics.

IMAC Holdings continues to lead healthcare innovations, while Ignite Proteomics sets new standards in personalized oncology care through advanced RPPA technology.